A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

Completed

• Conditions: Friedreich Ataxia
• Interventions: Diagnostic Test: Buccal Swabs and Blood Draws

• Registration Number: NCT04255680
• Lead Sponsor: Larimar Therapeutics, Inc.

Brief Summary

To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.

Detailed Description

Primary Objective:

The primary objective of this study is to identify whether frataxin levels and specific RNAs and proteins in blood and buccal cells differ between patients with FRDA and controls.

Secondary Objective:

The secondary objectives of this study are:

* To understand the variability of frataxin and specific RNAs and proteins identified in buccal cells.

* To correlate levels of frataxin and specific RNAs and proteins with features of FRDA.

* To correlate levels of frataxin and specific RNAs and proteins with triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL) levels, and other lipids.

Study Timeline

• Study Start: 2020-01-14
• Study First Submitted: 2020-02-03
• Study First Submitted QC: 2020-02-03
• Study First Posted: 2020-02-05
• Primary Completion: 2020-06-30
• Study Completion: 2020-06-30
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-17
• Last Update Posted: 2020-08-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male and female patients with FRDA confirmed by genetic testing (FRDA subjects only).
2. Children and adults between the ages of 12 and 65 (inclusive); age for controls will be +/- 2 years relative to FRDA subjects.
3. Subject (and/or parent/legal guardian) has voluntarily signed consent form.
4. Willingness and ability to comply with all study procedures.
5. Functional Disability Stage (FDS) of 3, 4, or 5 (FRDA subjects only).

Read More

Exclusion Criteria

1. Treatment with an investigational product within 30 days of study.
2. Use of gamma interferon or receiving any dose of gamma interferon within 90 days of the specimen collection day.
3. Use of any statin medications within 90 days of the specimen collection day.
4. Use of any lipid-lowering agents within 6 weeks of the specimen collection day.
5. Use of daily biotin supplementation that exceeds 30 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days of the study visit.
6. Pregnant women.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
FRDA Subjects	Buccal Swabs and Blood Draws	Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
Controlled Subjects	Buccal Swabs and Blood Draws	Male and female control subjects (matched by age \[+/- 2 years\] and sex)

Primary Outcome Measures

Name	Time	Method
Difference in frataxin levels, specific RNAs and proteins	1 day	Difference in frataxin levels, specific RNAs and proteins between FRDA patients and control patients.

Secondary Outcome Measures

Name	Time	Method
Correlation of frataxin levels, specific RNAs and proteins in FRDA patients	1 day	Correlation of frataxin levels, specific RNAs and proteins with features of FRDA in patients with FRDA.
Correlation of frataxin levels, specific RNAs and proteins	1 day	Correlation of frataxin levels, specific RNAs and proteins with triglycerides, HDL, LDL and other lipid levels between FRDA patients and control patients.
Variability in frataxin levels, specific RNAs and proteins	1 day	Variability in frataxin levels, specific RNAs and proteins between FRDA patients and control patients.

Trial Locations

Locations (1)

The Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States